Physician profile
Daniel V Santos
NPI 1669673075
$3,419.94
in general payments reported to CMS, 2019-2025
18 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $96.41 · 2021: $596 · 2022: $484 · 2023: $572 · 2024: $1,223 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280 · Consulting Fee: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.22 |
| Consulting Fee | $807.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $970.74 | 2022-2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Regeneron Healthcare Solutions, INC. | $778.91 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $373.97 | 2021-2025 | Nucala |
| Optinose US, INC. | $356.70 | 2019-2025 | |
| Genzyme Corporation | $296.08 | 2019-2025 | |
| Intersect Ent, INC. | $183.11 | 2020-2021 | |
| Acclarent, INC | $145.41 | 2021-2024 | Relieva Spinplus |
| Aerin Medical INC. | $58.15 | 2019-2025 | |
| Stryker Corporation | $56.56 | 2019-2024 | Scopis Ent |
| Hill Dermaceuticals, INC. | $28.98 | 2022-2023 | Tolak |
| Merck Sharp & Dohme LLC | $26.31 | 2021-2023 | |
| Ars Pharmaceuticals Operations, INC. | $25.07 | 2025 | Neffy |
| Glenmark Therapeutics INC. | $25.00 | 2019 | |
| Alk-Abello, INC | $23.36 | 2021 | |
| Hologic Sales and Service, LLC | $22.74 | 2023 | Coolseal Generator |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $18.63 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.84 | 2025 | Tezspire |
| Hikma Pharmaceuticals USA | $14.38 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Santos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.